Cardiology

Sara Diaz Saravia, MD, discusses a study from ESC Congress 2024 examining the utility of cancer history in women as a predictor of subclinical atherosclerosis.

Deepak Bhatt, MD, MPH, MBA, discusses common pitfalls for clinicians when interpreting trial data based on a presentation he led at ESC Congress 2024.

Women with endometriosis experienced a 20% greater risk of cardiac outcomes compared with women without endometriosis.

The STOP-or-NOT trial found similar outcomes for continuation or discontinuation of RAS inhibitors before noncardiac surgery, supporting individualized decision-making.

People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.

HELIOS-B trial shows vutrisiran reduces all-cause mortality and CV events in ATTR-CM, with benefits consistent regardless of tafamidis use.

The ABYSS trial suggests no clear benefit of continuing beta-blockers post-MI in patients with preserved LVEF, echoing REDUCE-AMI findings.

Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.

Kausik Ray, MD, discusses what trials and new data in lipidology he is most looking forward to from the upcoming ESC Congress.

Allegheny Health Network (AHN) Cardiovascular Institute is one of only a few centers offering intracoronary vascular brachytherapy, an innovative procedure providing hope for patients with challenging restenosis.

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.

A subgroup analysis of the SELECT trial confirmed semaglutide 2.4 mg benefits patients with heart failure across ejection fraction spectra, improving MACE and heart failure outcomes.

Cascade testing strategies significantly increased the detection of FH, with direct contact yielding a 16-fold higher testing rate, according to the IMPACT-FH study.

Laurence Sperling, MD, offers perspective on multiple topics within the evolving field of lipid management and dyslipidemia.

In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

A recent study found that noise exposure of power looms (≥ 85 decibels) puts workers at risk of their overall blood pressure increasing.

HIIT exercise post-stroke improved aerobic fitness more than MICT, with significant gains in peak VO2 after 12 weeks.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

New study suggests MRI-derived pressure measurements indicate a 5-fold increase in heart failure risk.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

In this episode, hosts are joined by Muthiah Vaduganathan, MD, MPH, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials.